Laurie E. Grove

2.2k citations

35 papers · 1.6k indexed · 1 hit paper · h-index 17

Impact in

Computational Theory and Mathematics top 1%
- Computational Drug Discovery Methods
Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research

Papers in

Pathology and Forensic Medicine 12
- Lymphoma Diagnosis and Treatment 12
Hematology 6
- Acute Myeloid Leukemia Research 5

Co-authors: Sándor Vajda Dima Kozakov Dmitri Beglov David R. Hall Tanggis Bohnuud Lingqi Luo Bing Xia Scott E. Mottarella
Journals: Blood (8 papers)Journal of Clinical Oncology (5 papers)Inorganic Chemistry (3 papers)Journal of the American Chemical Society (2 papers)Bioinformatics (2 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Laurie E. Grove

34 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins 2015 · 463 citations

Peers

Countries citing papers authored by Laurie E. Grove

Since Specialization

Citations

This map shows the geographic impact of Laurie E. Grove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurie E. Grove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurie E. Grove more than expected).

Fields of papers citing papers by Laurie E. Grove

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurie E. Grove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurie E. Grove. The network helps show where Laurie E. Grove may publish in the future.

Co-authors

The 25 scholars most cited alongside Laurie E. Grove, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurie E. Grove Line = papers co-authored together Laurie E. Grove links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Study on ion current density of different species in laser produced plasma in a solenoid magnet Journal of Physics Conference Series ·Takeshi Kanesue, Shunsuke Ikeda, M. Okamura, A. Cannavo, Giovanni Ceccio, Laurie E. Grove, Allan B. Friedland	2024	0
2	Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events Clinical journal of oncology nursing ·Kathleen Clifford, Amanda Copeland, Gregory Knutzen, Ellen Samuelson, Laurie E. Grove, Karen Schiavo	2018	6
3	The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins Nature Protocols ·Dima Kozakov, Laurie E. Grove, David R. Hall, Tanggis Bohnuud, Scott E. Mottarella, Lingqi Luo, Bing Xia, Dmitri Beglov, Sándor Vajda Hit paper breakdown →	2015	463
4	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Journal of Hematology & Oncology ·Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Pamela Levine, Laurie E. Grove, Andres Forero‐Torres	2014	136
5	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma Leukemia & lymphoma ·Tim Illidge, Réda Bouabdallah, Robert Chen, Ajay K. Gopal, Craig H. Moskowitz, Radhakrishnan Ramchandren, Andrei R. Shustov, Hervé Tilly, Tanya Trippett, Adam Gibb, Laurie E. Grove, Ranjana H. Advani	2014	26
6	CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies The Journal of Clinical Pharmacology ·Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Robert Chen, Jeffrey Matous, Maureen Cooper, Laurie E. Grove, Stephen C. Alley, Carmel M. Lynch, Owen A. O’Connor	2013	76
7	Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia Haematologica ·Mikkael A. Sekeres, J. E. Lancet, Brent L. Wood, Laurie E. Grove, Larissa Sandalic, Eric L. Sievers, Joseph G. Jurcic	2012	72
8	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. Blood ·Eric D. Jacobsen, Ranjana H. Advani, Yasuhiro Oki, Jeff P. Sharman, Sarah McCue Horwitz, Andres Forero‐Torres, Owen A. O’Connor, Andrei R. Shustov, Tanya Siddiqi, Laurie E. Grove, Nancy L. Bartlett	2012	9
9	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Blood ·Tim Illidge, Réda Bouabdallah, Robert W. Chen, Ajay K. Gopal, Craig H. Moskowitz, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Andrei R. Shustov, Hervé Tilly, Tanya Trippett, Laurie E. Grove, Ranjana H. Advani	2011	5
10	Robust Identification of Binding Hot Spots Using Continuum Electrostatics: Application to Hen Egg-White Lysozyme Journal of the American Chemical Society ·David H. Hall, Laurie E. Grove, Christine Yueh, Chi Ho Ngan, Dima Kozakov, Sándor Vajda	2011	25
11	Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study, Blood ·Jeffrey E. Lancet, Mikkael A. Sekeres, Brent L. Wood, Laurie E. Grove, Larissa Sandalic, Eric L. Sievers, Joseph G. Jurcic	2011	7
12	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), Blood ·Andres Forero‐Torres, R.B. Berryman, Ranjana H. Advani, Nancy L. Bartlett, Robert W. Chen, Michelle A. Fanale, Ajay K. Gopal, Owen A. O’Connor, Randal Olshefski, Scott E. Smith, Laurie E. Grove, Jeffrey Matous	2011	9
13	Structural conservation of druggable hot spots in protein–protein interfaces Proceedings of the National Academy of Sciences ·Dima Kozakov, David R. Hall, Gwo‐Yu Chuang, Regina Cencic, Ryan Brenke, Laurie E. Grove, Dmitri Beglov, Jerry Pelletier, Adrian Whitty, Sándor Vajda	2011	186
14	Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial Leukemia & lymphoma ·Azra Raza, Joseph G. Jurcic, Gail J. Roboz, Michael B. Maris, Joseph J. Stephenson, Brent L. Wood, Eric J. Feldman, Naomi Galili, Laurie E. Grove, Jonathan G. Drachman, Eric L. Sievers	2009	49
15	Spectroscopic and Computational Insights into Second-Sphere Amino-Acid Tuning of Substrate Analogue/Active-Site Interactions in Iron(III) Superoxide Dismutase Inorganic Chemistry ·Laurie E. Grove, Juan Xie, Emine Yikilmaz, Anush V. Karapetyan, Anne‐Frances Miller, Thomas C. Brunold	2008	16
16	SECOND-SPHERE TUNING OF THE METAL ION REDUCTION POTENTIALS IN IRON AND MANGANESE SUPEROXIDE DISMUTASES Comments on Inorganic Chemistry ·Laurie E. Grove, Thomas C. Brunold	2008	35
17	Synthesis, X-Ray Crystallographic Characterization, and Electronic Structure Studies of a Di-Azide Iron(III) Complex: Implications for the Azide Adducts of Iron(III) Superoxide Dismutase Inorganic Chemistry ·Laurie E. Grove, Jason K. Hallman, Joseph P. Emerson, J.A. Halfen, Thomas C. Brunold	2008	10
18	Spectroscopic and Computational Investigation of Second-Sphere Contributions to Redox Tuning in Escherichia coli Iron Superoxide Dismutase Inorganic Chemistry ·Laurie E. Grove, Juan Xie, Emine Yikilmaz, Anne‐Frances Miller, Thomas C. Brunold	2008	31
19	A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma Lung Cancer ·Helen J. Ross, Lowell L. Hart, Paul Swanson, Mark U. Rarick, Robert A. Figlin, Andrew Jacobs, David McCune, Arthur Rosenberg, Ari David Baron, Laurie E. Grove, Michael Thorn, Dennis M. Miller, Jonathan G. Drachman, Charles M. Rudin	2006	29
20	Carbon–sulfur bond cleavage and reduction of thiols and dithioethers under oxidative conditions Dalton Transactions ·Joseph E. Remias, Laurie E. Grove, Ayusman Sen	2003	2

About Laurie E. Grove

Laurie E. Grove is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Oncology and Inorganic Chemistry, having authored 35 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (12 papers), Protein Structure and Dynamics (6 papers), Acute Myeloid Leukemia Research (5 papers), HER2/EGFR in Cancer Research (5 papers), CO2 Reduction Techniques and Catalysts (5 papers), Metal-Catalyzed Oxygenation Mechanisms (5 papers), Enzyme Structure and Function (5 papers) and Computational Drug Discovery Methods (4 papers). The work is most often cited by research in Computational Theory and Mathematics (369 citations), Oncology (506 citations), Pathology and Forensic Medicine (319 citations), Molecular Biology (842 citations) and Dermatology (92 citations). Laurie E. Grove has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Sándor Vajda, Dima Kozakov, Dmitri Beglov, David R. Hall, Tanggis Bohnuud, Lingqi Luo, Bing Xia, Scott E. Mottarella, David Hall and Brandon S. Zerbe. Their work appears in journals such as Blood, Journal of Clinical Oncology, Inorganic Chemistry, Journal of the American Chemical Society and Bioinformatics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact